{"id":"bcx4161","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297502","moleculeType":"Small molecule","molecularWeight":"513.55"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BCX4161 works by inhibiting the C1 inhibitor, which is a key component of the classical pathway of the complement system. This inhibition leads to the activation of the complement system, which helps to eliminate pathogens and damaged cells. By modulating the complement system, BCX4161 may help to reduce inflammation and improve immune function.","oneSentence":"BCX4161 is a small molecule inhibitor of the C1 inhibitor of the complement system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:52.469Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hereditary angioedema"}]},"trialDetails":[{"nctId":"NCT07228559","phase":"PHASE1","title":"A Study of Avoralstat In Participants With Diabetic Macular Edema","status":"RECRUITING","sponsor":"BioCryst Pharmaceuticals","startDate":"2025-10-02","conditions":"Diabetic Macular Edema (DME)","enrollment":9},{"nctId":"NCT02303626","phase":"PHASE2, PHASE3","title":"12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2014-12-17","conditions":"Hereditary Angioedema, HAE","enrollment":110},{"nctId":"NCT02670720","phase":"PHASE3","title":"Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2015-12","conditions":"Hereditary Angioedema, HAE","enrollment":6},{"nctId":"NCT02218294","phase":"PHASE1","title":"Study to Determine How BCX4161 is Metabolized and Eliminated by the Body","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2014-08","conditions":"Hereditary Angioedema","enrollment":7},{"nctId":"NCT01984788","phase":"PHASE2","title":"Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2013-11","conditions":"Hereditary Angioedema","enrollment":24},{"nctId":"NCT02125162","phase":"PHASE1","title":"A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2014-04","conditions":"Hereditary Angioedema","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BCX4161","genericName":"BCX4161","companyName":"BioCryst Pharmaceuticals","companyId":"biocryst-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCX4161 is a small molecule inhibitor of the C1 inhibitor of the complement system. Used for Hereditary angioedema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}